Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – Analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Plus Therapeutics in a research report issued on Friday, November 15th. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of $0.28 for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.
Separately, Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.
Plus Therapeutics Stock Performance
Shares of PSTV stock opened at $1.17 on Monday. Plus Therapeutics has a 1 year low of $1.15 and a 1 year high of $2.78. The stock has a market cap of $6.90 million, a PE ratio of -0.46 and a beta of 0.69. The business’s fifty day moving average is $1.40 and its 200-day moving average is $1.67.
Hedge Funds Weigh In On Plus Therapeutics
A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics as of its most recent SEC filing. 3.28% of the stock is currently owned by institutional investors and hedge funds.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Featured Stories
- Five stocks we like better than Plus Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- How to Calculate Inflation Rate
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Stock Sentiment Analysis: How it Works
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
